Amarin (AMRN): Goldman Remains Neutral as Investors Await FDA Response on ANCHOR Appeal
Tweet Send to a Friend
Goldman Sachs maintained a Neutral rating on Amarin Corporation (NASDAQ: AMRN) with a price target of $1.90. Comments follow Q2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
